Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 65.78% is 36% above its 5-year average of 48.30%, near the high end of its 5-year range (25.98%–68.07%).
As of the fiscal period ended Tuesday, June 30, 2026. 2.81% above its 12-month average of 63.99%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 65.78%.
DEBT TO ASSETS RATIO
65.78%
DEBT TO ASSETS RATIO AVG TTM
63.99%
DEBT TO ASSETS RATIO AVG 3Y
61.93%
DEBT TO ASSETS RATIO AVG 5Y
48.30%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+2.81%
CURRENT VS 3Y AVG
+6.22%
CURRENT VS 5Y AVG
+36.20%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+72991.61%
vs the sector median at left
Neuronetics, Inc.
Market Cap
$154.14M
Debt to Assets Ratio
65.78%
TTM Avg
63.99%
3Y Avg
61.93%
5Y Avg
48.30%
Market Cap
$152.82M
Debt to Assets Ratio
0.89%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$149.28M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.69M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.48M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$160.02M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuronetics, Inc. (STIM) | $154.14M | 65.78% | 63.99% | 61.93% | 48.30% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $152.82M | 0.89% | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.90M | 0.06% | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $149.28M | 0.00% | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | 0.10% | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $148.97M | 0.60% | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $148.69M | 0.06% | N/A | N/A | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $148.48M | N/A | N/A | N/A | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $160.02M | 0.00% | N/A | N/A | N/A |
| PepGen Inc. (PEPG)vs › | $160.13M | 0.11% | N/A | N/A | N/A |
Debt/Assets
65.8%
Debt/Equity
4.85
Current Ratio
1.88
Interest Coverage
-3.7x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 65.78% |
| 2026-03-31 | 68.07% |
| 2025-12-31 | 63.80% |
| 2025-09-30 | 62.39% |
| 2025-06-30 | 59.90% |
| 2025-03-31 | 58.13% |
| 2024-12-31 | 58.64% |
| 2024-09-30 | 65.70% |
| 2024-06-30 | 64.68% |
| 2024-03-31 | 60.18% |
| 2023-12-31 | 53.94% |
| 2023-09-30 | 43.23% |
| 2023-06-30 | 40.05% |
| 2023-03-31 | 38.89% |
| 2022-12-31 | 34.00% |
| 2022-09-30 | 33.29% |
| 2022-06-30 | 32.22% |
| 2022-03-31 | 30.45% |
| 2021-12-31 | 28.00% |
| 2021-09-30 | 26.94% |
| 2021-06-30 | 25.98% |
| 2021-03-31 | 25.22% |
| 2020-12-31 | 48.74% |
| 2020-09-30 | 48.95% |
| 2020-06-30 | 47.78% |
| 2020-03-31 | 43.12% |
| 2019-12-31 | 34.27% |
| 2019-09-30 | 33.63% |
| 2019-06-30 | 32.38% |
| 2019-03-31 | 30.70% |
| 2018-12-31 | 25.97% |
| 2018-09-30 | 25.38% |
| 2018-06-30 | 105.83% |
| 2018-03-31 | 93.09% |
| 2017-12-31 | 75.91% |
